These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 17195945)

  • 41. A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer.
    Han JY; Lee DH; Kim HY; Kim EA; Lee JJ; Ju SY; Shin EH; Lee JS
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5909-14. PubMed ID: 14676114
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies.
    Gore L; Rivera E; Basche M; Moulder-Thompson SL; Li J; Eppers S; Grolnic S; O'Bryant C; Cleere D; Elsayed YA; Eckhardt SG
    Invest New Drugs; 2012 Oct; 30(5):1942-9. PubMed ID: 21931969
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors.
    Fakih MG; Pendyala L; Smith PF; Creaven PJ; Reid ME; Badmaev V; Azrak RG; Prey JD; Lawrence D; Rustum YM
    Clin Cancer Res; 2006 Feb; 12(4):1237-44. PubMed ID: 16489079
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of capecitabine and oxaliplatin combination as second-line treatment in advanced colorectal cancer.
    Heras P; Kritikos K; Hatzopoulos A; Xourafas V; Kritikos N; Karagiannis S; Mitsibounas D
    Am J Ther; 2009; 16(4):319-22. PubMed ID: 19352139
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.
    Jimeno A; Rudek MA; Purcell T; Laheru DA; Messersmith WA; Dancey J; Carducci MA; Baker SD; Hidalgo M; Donehower RC
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):423-33. PubMed ID: 17429623
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation.
    Allegrini G; Di Paolo A; Cerri E; Cupini S; Amatori F; Masi G; Danesi R; Marcucci L; Bocci G; Del Tacca M; Falcone A
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):585-93. PubMed ID: 16680463
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer.
    Bleickardt E; Argiris A; Rich R; Blum K; McKeon A; Tara H; Zelterman D; Burtness B; Davies MJ; Murren JR
    Cancer Biol Ther; 2002; 1(6):646-51. PubMed ID: 12642688
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
    O'connor T; Rustum Y; Levine E; Creaven P
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies.
    Villalona-Calero MA; Weiss GR; Burris HA; Kraynak M; Rodrigues G; Drengler RL; Eckhardt SG; Reigner B; Moczygemba J; Burger HU; Griffin T; Von Hoff DD; Rowinsky EK
    J Clin Oncol; 1999 Jun; 17(6):1915-25. PubMed ID: 10561233
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity.
    Borner MM; Bernhard J; Dietrich D; Popescu R; Wernli M; Saletti P; Rauch D; Herrmann R; Koeberle D; Honegger H; Brauchli P; Lanz D; Roth AD;
    Ann Oncol; 2005 Feb; 16(2):282-8. PubMed ID: 15668285
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine.
    Infante JR; Jones SF; Bendell JC; Greco FA; Yardley DA; Lane CM; Spigel DR; Hainsworth JD; Burris HA
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):137-44. PubMed ID: 21626051
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies.
    Comella P; Casaretti R; De Rosa V; Avallone A; Izzo F; Fiore F; Lapenta L; Comella G
    Ann Oncol; 2002 Dec; 13(12):1874-81. PubMed ID: 12453855
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer.
    Scheithauer W; Kornek GV; Raderer M; Schüll B; Schmid K; Längle F; Huber H
    Ann Oncol; 2002 Oct; 13(10):1583-9. PubMed ID: 12377646
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
    Soepenberg O; Dumez H; Verweij J; de Jong FA; de Jonge MJ; Thomas J; Eskens FA; van Schaik RH; Selleslach J; Ter Steeg J; Lefebvre P; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
    Clin Cancer Res; 2005 Feb; 11(4):1504-11. PubMed ID: 15746053
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preoperative downstaging chemoradiation with concurrent irinotecan and capecitabine in MRI-defined locally advanced rectal cancer: a phase I trial (NWCOG-2).
    Gollins SW; Myint S; Susnerwala S; Haylock B; Wise M; Topham C; Samuel L; Swindell R; Morris J; Mason L; Levine E
    Br J Cancer; 2009 Sep; 101(6):924-34. PubMed ID: 19690550
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study.
    Briasoulis E; Golfinopoulos V; Karina M; Papakostas P; Pavlidis N; Fountzilas G
    Anticancer Drugs; 2010 Sep; 21(8):785-9. PubMed ID: 20647930
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors.
    Drengler RL; Kuhn JG; Schaaf LJ; Rodriguez GI; Villalona-Calero MA; Hammond LA; Stephenson JA; Hodges S; Kraynak MA; Staton BA; Elfring GL; Locker PK; Miller LL; Von Hoff DD; Rothenberg ML
    J Clin Oncol; 1999 Feb; 17(2):685-96. PubMed ID: 10080615
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group.
    Garcia-Alfonso P; Muñoz-Martin A; Mendez-Ureña M; Quiben-Pereira R; Gonzalez-Flores E; Perez-Manga G
    Br J Cancer; 2009 Oct; 101(7):1039-43. PubMed ID: 19738605
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors.
    Camidge DR; Gail Eckhardt S; Gore L; O'Bryant CL; Leong S; Basche M; Holden SN; Musib L; Baldwin J; Darstein C; Thornton D; Finn RS; Britten CD
    Anticancer Drugs; 2008 Jan; 19(1):77-84. PubMed ID: 18043132
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer.
    Cohen SJ; Gallo J; Lewis NL; Alpaugh RK; Gentner L; Rogatko A; Yeslow G; Schol J; Verhaeghe T; Zannikos P; Palmer PA; Weiner LM; Meropol NJ
    Cancer Chemother Pharmacol; 2004 Jun; 53(6):513-8. PubMed ID: 14760509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.